Sepracor announced in a regulatory filing that Teva Pharmaceuticals USA and Cobalt Laboratories requested FDA approval to produce a version of Sepracor's sleep drug Lunesta, which gained U.S. clearance in 2004. Sepracor said it intends to file a patent suit to delay the approval of the abbreviated new-drug applications.

Related Summaries